FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011567222> ?p ?o ?g. }

• W2011567222 endingPage "03" @default.
• W2011567222 startingPage "P1" @default.
• W2011567222 abstract "Abstract Introduction: TACT, an investigator-led study in 4162 women with node positive (N+ve) or high risk node negative (N-ve) early breast cancer (EBC), is the largest taxane trial unconfounded by treatment (trt) duration. At principal analysis, with 5 years follow-up (fup), no evidence of improved disease-free survival (DFS) was observed by switching to 4 cycles of docetaxel (D) after 4 cycles of FEC (Ellis, Lancet 2009). Results were provocative in suggesting differential effects according to ER & HER2 status. Longer fup provides opportunity to detect emergence of late trt effects overall & within phenotypic subgroups & explore patterns of recurrence, by tumor characteristics. Patients & methods: TACT recruited women with histologically confirmed completely resected invasive EBC from 104 centers (UK (103), Belgium (1)) between 02/2001 & 07/2003. Centers chose FEC (600/60/600 mg/m2 q3wk × 8) or E-CMF (E 100mg/m2 q3wk × 4 → CMF 100mg/m2 PO d1-14 or 600mg/m2 IV d1&8/40/600 mg/m2 q4wk × 4) as their control, reflecting standard UK practice. Patients (pts) were randomized to FEC-D (FEC q3wk × 4 → D 100 mg/m2 q3wk × 4) or control. 2523 pts were from FEC centers (FEC = 1265: FEC-D = 1258) & 1639 from E-CMF centers (E-CMF = 824; FEC-D = 815). Endocrine therapy was given for 5 years. Few pts received HER2 directed therapy; 589 pts had unknown HER2 status. Median fup is now 97.5 months; this analysis updates DFS & overall survival in the ITT population. It also explores patterns of relapse by phenotypic & clinical characteristics. Analyses of trt effect are stratified by ER status due to issues of non-proportionality of hazard associated with length of fup. Results: DFS events have been reported for 1329 pts (FEC-D=640, Control=689) giving an unadjusted hazard ratio (HR) & 95%CI (stratified by control regimen & ER status) of 0.93 (0.83, 1.03) overall; p = 0.16 in favor of FEC-D & for ER+ve/HER2-ve of 0.99 (0.84, 1.17), for ER+ve/HER2+ve) 0.97 (0.73, 1.30), for ER-ve/HER2+ve 0.74 (0.53, 1.03), & ER-ve/HER2-ve 0.93 (0.73, 1.17). 1017 patients have died (FEC-D=500, Control=517); unadjusted HR=0.98 (95%CI: 0.86, 1.10); p = 0.69 with intercurrent deaths (prior to distant relapse) reported for 80 pts (FEC-D=40, Control=40). Annual event rates show different pattern of disease relapse by phenotypic subgroup Graphical representation will further explore these patterns & associated sites of relapse. Discussion: With a median fup of &gt;8 years no clear benefit has emerged for D over standard anthracyclines within the TACT pt group. Differential effects associated with different patterns of relapse remain of interest. TACT precedes use of antiHER2 therapy which is known to have impacted on early relapse risk in HER2+ve pts. The high relapse risk observed for pts with ER-ve/HER2-ve disease remains a current clinical challenge. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P1-13-03." @default.
• W2011567222 created "2016-06-24" @default.
• W2011567222 creator A5006665510 @default.
• W2011567222 creator A5007286394 @default.
• W2011567222 creator A5010153233 @default.
• W2011567222 creator A5019873801 @default.
• W2011567222 creator A5021168213 @default.
• W2011567222 creator A5033149434 @default.
• W2011567222 creator A5040167724 @default.
• W2011567222 creator A5055361911 @default.
• W2011567222 creator A5056232227 @default.
• W2011567222 creator A5057465917 @default.
• W2011567222 creator A5057689412 @default.
• W2011567222 creator A5065272343 @default.
• W2011567222 creator A5073888459 @default.
• W2011567222 creator A5074043299 @default.
• W2011567222 creator A5075442632 @default.
• W2011567222 creator A5078289135 @default.
• W2011567222 creator A5083306545 @default.
• W2011567222 creator A5087254676 @default.
• W2011567222 date "2012-12-01" @default.
• W2011567222 modified "2023-10-01" @default.
• W2011567222 title "Abstract P1-13-03: Mature analysis of UK Taxotere as Adjuvant Chemotherapy (TACT) trial (CRUK 01/001); effects of treatment and characterisation of patterns of breast cancer relapse." @default.
• W2011567222 doi "https://doi.org/10.1158/0008-5472.sabcs12-p1-13-03" @default.
• W2011567222 hasPublicationYear "2012" @default.
• W2011567222 type Work @default.
• W2011567222 sameAs 2011567222 @default.
• W2011567222 citedByCount "2" @default.
• W2011567222 countsByYear W20115672222014 @default.
• W2011567222 countsByYear W20115672222019 @default.
• W2011567222 crossrefType "journal-article" @default.
• W2011567222 hasAuthorship W2011567222A5006665510 @default.
• W2011567222 hasAuthorship W2011567222A5007286394 @default.
• W2011567222 hasAuthorship W2011567222A5010153233 @default.
• W2011567222 hasAuthorship W2011567222A5019873801 @default.
• W2011567222 hasAuthorship W2011567222A5021168213 @default.
• W2011567222 hasAuthorship W2011567222A5033149434 @default.
• W2011567222 hasAuthorship W2011567222A5040167724 @default.
• W2011567222 hasAuthorship W2011567222A5055361911 @default.
• W2011567222 hasAuthorship W2011567222A5056232227 @default.
• W2011567222 hasAuthorship W2011567222A5057465917 @default.
• W2011567222 hasAuthorship W2011567222A5057689412 @default.
• W2011567222 hasAuthorship W2011567222A5065272343 @default.
• W2011567222 hasAuthorship W2011567222A5073888459 @default.
• W2011567222 hasAuthorship W2011567222A5074043299 @default.
• W2011567222 hasAuthorship W2011567222A5075442632 @default.
• W2011567222 hasAuthorship W2011567222A5078289135 @default.
• W2011567222 hasAuthorship W2011567222A5083306545 @default.
• W2011567222 hasAuthorship W2011567222A5087254676 @default.
• W2011567222 hasConcept C121608353 @default.
• W2011567222 hasConcept C126322002 @default.
• W2011567222 hasConcept C143998085 @default.
• W2011567222 hasConcept C15744967 @default.
• W2011567222 hasConcept C2776694085 @default.
• W2011567222 hasConcept C2777511904 @default.
• W2011567222 hasConcept C2778833722 @default.
• W2011567222 hasConcept C2779786085 @default.
• W2011567222 hasConcept C2781164504 @default.
• W2011567222 hasConcept C2781190966 @default.
• W2011567222 hasConcept C2908647359 @default.
• W2011567222 hasConcept C29456083 @default.
• W2011567222 hasConcept C530470458 @default.
• W2011567222 hasConcept C542102704 @default.
• W2011567222 hasConcept C71924100 @default.
• W2011567222 hasConcept C99454951 @default.
• W2011567222 hasConceptScore W2011567222C121608353 @default.
• W2011567222 hasConceptScore W2011567222C126322002 @default.
• W2011567222 hasConceptScore W2011567222C143998085 @default.
• W2011567222 hasConceptScore W2011567222C15744967 @default.
• W2011567222 hasConceptScore W2011567222C2776694085 @default.
• W2011567222 hasConceptScore W2011567222C2777511904 @default.
• W2011567222 hasConceptScore W2011567222C2778833722 @default.
• W2011567222 hasConceptScore W2011567222C2779786085 @default.
• W2011567222 hasConceptScore W2011567222C2781164504 @default.
• W2011567222 hasConceptScore W2011567222C2781190966 @default.
• W2011567222 hasConceptScore W2011567222C2908647359 @default.
• W2011567222 hasConceptScore W2011567222C29456083 @default.
• W2011567222 hasConceptScore W2011567222C530470458 @default.
• W2011567222 hasConceptScore W2011567222C542102704 @default.
• W2011567222 hasConceptScore W2011567222C71924100 @default.
• W2011567222 hasConceptScore W2011567222C99454951 @default.
• W2011567222 hasIssue "24_Supplement" @default.
• W2011567222 hasLocation W20115672221 @default.
• W2011567222 hasOpenAccess W2011567222 @default.
• W2011567222 hasPrimaryLocation W20115672221 @default.
• W2011567222 hasRelatedWork W2091007248 @default.
• W2011567222 hasRelatedWork W2147874203 @default.
• W2011567222 hasRelatedWork W2163622510 @default.
• W2011567222 hasRelatedWork W2405779492 @default.
• W2011567222 hasRelatedWork W2727568273 @default.
• W2011567222 hasRelatedWork W3010153683 @default.
• W2011567222 hasRelatedWork W3173641743 @default.
• W2011567222 hasRelatedWork W4200451232 @default.
• W2011567222 hasRelatedWork W4221084097 @default.
• W2011567222 hasRelatedWork W4287922124 @default.
• W2011567222 hasVolume "72" @default.
• W2011567222 isParatext "false" @default.
• W2011567222 isRetracted "false" @default.

• next